Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
NCT06862648
Recruiting
The goal of this pivotal clinical trial is to evaluate the safety and effectiveness of the SUI-100 device for the treatment of mild-to-moderate stress urinary incontinence (SUI) in females aged 22-70 years. The main questions this study aims to answer are: 1. Does treatment with the SUI-100 device reduce SUI symptoms, as measured by urine leakage. 2. Is the device safe and effective compared to the sham group? Participants will: 1. Be randomly assigned to an active or sham control group in a... Read More
Gender:
FEMALE
Ages:
Between 22 years and 77 years
Trial Updated:
05/23/2025
Locations: Arizona Gynecology Consultants, Phoenix, Arizona +6 locations
Conditions: Stress Urinary Incontinence (SUI)
Register for Updates
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
NCT06921759
Recruiting
The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/23/2025
Locations: Medical Dermatology Specialists, Phoenix, Arizona +83 locations
Conditions: Atopic Hand and Foot Dermatitis
Register for Updates
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
NCT06954337
Recruiting
Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care. MSK's goal is to make getting cancer care easier by cutting down the need to make in-person visits to MSK. MSK is trying to do this through a new option called enhanced telehealth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Prostate Cancer
Register for Updates
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
NCT06983743
Recruiting
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/23/2025
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Metastatic Solid Tumors
Register for Updates
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
NCT00209235
Recruiting
We, the researchers, are following the natural history of Albright hereditary osteodystrophy. We have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1A, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1A typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evalua... Read More
Gender:
ALL
Ages:
Between 2 months and 89 years
Trial Updated:
05/23/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Pseudohypoparathyroidism Type 1A, Albright Hereditary Osteodystrophy, Pseudopseudohypoparathyroidism
Register for Updates
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
NCT02531880
Recruiting
Background: - The blood-brain barrier separates the brain from the rest of the body. Epilepsy is a neurological disease that causes seizures. It can affect this barrier. Researchers think a contrast agent called mangafodipir might be better able to show areas of the brain that epilepsy affects. Objective: - To see if mangafodipir is well tolerated and safe. To see if it can show, on an MRI, areas of the brain that epilepsy affects. Eligibility: * People ages 18-60 who: * Have epilepsy not c... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/23/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Epilepsy
Register for Updates
Neural Correlates of Hypoalgesia Driven by Observation
NCT03897998
Recruiting
Placebo effects held an ambivalent place in health care for at least two centuries. On the one hand, placebos are traditionally used as controls in clinical trials to correct for biases and the placebo response is viewed as an effect to be factored out in order to isolate and accurately measure the effects of the treatment. On the other hand, there is scientific evidence that placebo effects represent fascinating psychoneurobiological events involving the contribution of distinct central nervous... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/23/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: Pain, Virtual Reality, Placebo
Register for Updates
Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy
NCT04468932
Recruiting
The objective of this proposal is to investigate the effect of non-invasive repetitive cerebellar transcranial magnetic stimulation (rTMS) on motor control in progressive supranuclear (PSP). The central hypothesis is that augmenting cerebellar inhibition via cerebellar rTMS will decrease postural instability in patients with PSP. We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
05/23/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Palsy Supranuclear, Supranuclear Palsy, Progressive
Register for Updates
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain
NCT04851301
Recruiting
This project examines, in chronic pain, the mechanisms of immersive virtual reality compared to the mechanisms of placebo hypoalgesia. The potential of developing new non-pharmacological premises for low-risk interventions for pain management is high.
Gender:
ALL
Ages:
Between 18 years and 88 years
Trial Updated:
05/23/2025
Locations: Luana Colloca, Baltimore, Maryland
Conditions: Pain, Virtual Reality, Placebo, Temporomandibular Disorder
Register for Updates
VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey
NCT05037305
Recruiting
The field of pharmacogenetics has progressed from the discovery of genetic variants that cause variable function of drug metabolism enzymes to a cornerstone of clinical precision medicine. However, there are limited data supporting drug-gene associations for children and for women during and after pregnancy. The unique physiology of childhood and pregnancy demand validation of pharmacogenetic signals prior to clinical implementation. These knowledge gaps are compounded for individuals from minor... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/23/2025
Locations: Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee +1 locations
Conditions: Pharmacogenomic Testing
Register for Updates
Supporting Treatment Access and Recovery in COD
NCT05138614
Recruiting
This 4-year study will randomize 1,000 people with co-occurring opioid use and mental health disorders (COD) at medication for opioid use disorder (MOUD) clinics to evaluate the effectiveness of MISSION, a multi-component team approach, or its components with MOUD versus MOUD alone, as well as the incremental benefits of MISSION or its components for improving outcomes. We expect that individuals receiving MISSION or its parts + MOUD will show greater improvement over MOUD alone on: engagement,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Behavioral Health Network, Holyoke, Massachusetts +4 locations
Conditions: Opioid Use Disorder, Mental Health Disorder
Register for Updates
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT05422794
Recruiting
This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to other parts of the body (advanced). Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanopar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Boston Medical Center, Boston, Massachusetts +3 locations
Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Register for Updates